CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aethlon Medical, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aethlon Medical, Inc.
11555 Sorrento Valley Road, Suite 203
Phone: (619) 941-0360p:619 941-0360 SAN DIEGO, CA  92121  United States Ticker: AEMDAEMD
Business Summary
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024YesYes---

Industries
SIC Code Description
3826 Laboratory analytical instruments
3845 Electromedical and electrotherapeutic apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Edward G.Broenniman 87 10/30/2020 3/10/1999
Chief Executive Officer, Chief Financial Officer, Director James B.Frakes 66 10/3/2024 1/1/2008
Chief Medical Officer Steven P.Larosa 57 2/1/2023 1/4/2021
3 additional Officers and Directors records available in full report.

Business Names
Business Name
AEMD
Aethlon Medical Australia Pty Ltd
Aethlon Medical, Inc.

General Information
Number of Employees: 14 (As of 3/31/2024)
Outstanding Shares: 13,961,998 (As of 11/6/2024)
Shareholders: 62
Stock Exchange: NASD
Federal Tax Id: 133632859


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024